Medicinova, Inc. - MNOV STOCK NEWS

MediciNova announced data from their Phase 1b/2a clinical trial of MN-166 (ibudilast) combined with Temozolomide (TMZ) in glioblastoma patients at the ASCO Annual Meeting 2024. The study included 62 patients, split between newly diagnosed (36) and recurrent (26) GBM cases. Primary endpoints were safety, tolerability, and efficacy. The combination treatment was safe and well-tolerated, with no unexpected adverse effects. Progression-Free Survival at 6 months (PFS6) was 44% for new and 31% for recurrent GBM, higher than historical controls in recurrent cases. Median PFS was 8.7 months for new and 2.4 months for recurrent GBM. Median Overall Survival was 21 months for new and 8.6 months for recurrent GBM. Preclinical data suggests improved survival with MN-166 and PD-1/PD-L1 antibody therapy combination. Future trials will evaluate this combination further.

MediciNova announced two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress. The presentations highlighted the efficacy, safety, and tolerability of MN-001 (Tipelukast) for non-alcoholic fatty liver disease (NAFLD) and its metabolite MN-002's effects on cholesterol efflux. The Phase 2 clinical trial for MN-001 has enrolled 33 patients, with 14 completing the study. Three serious adverse events were reported but deemed unrelated to the drug. MN-002 was shown to significantly enhance cholesterol efflux and protein expression in a dose-dependent manner, with notable increases in ABCA1 and ABCG1 mRNA levels.

MediciNova, a biopharmaceutical company listed on NASDAQ and Tokyo Stock Exchange, announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-166 (ibudilast) for preventing metastasis in eye cancer. The patent, expected to expire by July 2042, covers the use of MN-166 for uveal melanoma, detailing various doses, frequencies, and treatment periods. MN-166 impedes uveal melanoma migration by inhibiting the macrophage migration inhibitory factor and reducing immune suppressive cells, enhancing CD8 T cell activity. The company views this patent as enhancing the potential value of MN-166 in oncology.

MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering MN-166 (ibudilast) for treating chlorine-induced acute respiratory distress syndrome (ARDS). This patent, expected to expire no earlier than January 2042, includes claims for MN-166 as a monotherapy or in combination with other drugs, and covers various administration methods and dosing frequencies. The announcement follows a promising nonclinical model study showing significant improvements in pulmonary function and survival rates with MN-166. Chief Medical Officer Kazuko Matsuda expressed optimism about the potential value this patent adds to MN-166.

MediciNova, Inc. has received a new patent from the U.S. Patent and Trademark Office covering extended-release formulations of MN-166 (ibudilast), set to expire after September 2040. The patent includes claims for tablet or capsule formulations at various doses. Chief Medical Officer, Kazuko Matsuda, sees this patent as enhancing the value of MN-166 by offering patient convenience and potentially reducing side effects.

MediciNova, Inc. announced the selection of an abstract for an oral presentation at the 2024 ASCO Annual Meeting on the results of a clinical trial of MN-166 in glioblastoma. The presentation will be given by Dr. Gilbert Youssef, detailing a Phase 1b/2a study on the combination of MN-166 and temozolomide in patients with newly diagnosed and recurrent GBM.

MediciNova, Inc. receives a Notice of Allowance from the Japan Patent Office for a pending patent application covering MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039 and covers a wide range of doses, dosing frequencies, and treatment periods. Chief Medical Officer, Kazuko Matsuda, highlights the potential value of MN-166 in ophthalmic neurodegenerative diseases based on positive data from previous studies.

MediciNova, Inc. announces abstracts on MN-001's efficacy in NAFLD, HTG, and T2DM accepted for EAS 2024 Congress. Chief Medical Officer to present ongoing clinical trial design and results of research on MN-001 and MN-002.

MediciNova, Inc. announces positive results from a nonclinical study evaluating MN-166 (ibudilast) in a chlorine gas-induced acute lung injury model. MN-166 showed significant improvements in pulmonary function, survival rates, and lung injury attenuation. The study highlighted the efficacy of MN-166 in treating acute lung injury, positioning it as a promising candidate for further development.